新京报讯(记者王卡拉)近日,美国《制药经理人》杂志(Pharm Exec)公布2025年全球制药企业50强榜单,榜单TOP10均被跨国药企包揽,强生以557.45亿美元的销售收入高居榜首。榜单中还有6家中国药企上榜,创历史新高。在创新药舞台上,中国药企已经崭露头角,与跨国药企的距离逐渐拉近,在有些领域甚至实现超越。 GSK退出TOP10,诺和诺德挺进 2025年全球制药50强榜单按照2024...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.